233 related articles for article (PubMed ID: 22752863)
1. Antimicrobial activities of fidaxomicin.
Goldstein EJ; Babakhani F; Citron DM
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S143-8. PubMed ID: 22752863
[TBL] [Abstract][Full Text] [Related]
2. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
[TBL] [Abstract][Full Text] [Related]
3. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
4. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
[TBL] [Abstract][Full Text] [Related]
5. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Babakhani F; Gomez A; Robert N; Sears P
J Med Microbiol; 2011 Aug; 60(Pt 8):1213-1217. PubMed ID: 21349983
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
7. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
8. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Allen CA; Babakhani F; Sears P; Nguyen L; Sorg JA
Antimicrob Agents Chemother; 2013 Jan; 57(1):664-7. PubMed ID: 23147724
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates.
Eitel Z; Terhes G; Sóki J; Nagy E; Urbán E
Anaerobe; 2015 Feb; 31():47-9. PubMed ID: 25139122
[TBL] [Abstract][Full Text] [Related]
11. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.
Babakhani F; Seddon J; Robert N; Shue YK; Sears P
Antimicrob Agents Chemother; 2010 Jun; 54(6):2674-6. PubMed ID: 20308366
[TBL] [Abstract][Full Text] [Related]
12. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
[TBL] [Abstract][Full Text] [Related]
13. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD.
Walsh L; Lavelle A; O'Connor PM; Hill C; Ross RP
Gut Microbes; 2024; 16(1):2342583. PubMed ID: 38722061
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118.
Yanagihara K; Akamatsu N; Matsuda J; Kaku N; Katsumata K; Kosai K
J Infect Chemother; 2018 Jun; 24(6):492-495. PubMed ID: 29373265
[TBL] [Abstract][Full Text] [Related]
16. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Babakhani F; Gomez A; Robert N; Sears P
Antimicrob Agents Chemother; 2011 Sep; 55(9):4427-9. PubMed ID: 21709084
[TBL] [Abstract][Full Text] [Related]
17. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
Takeda S; Miki T
Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
[TBL] [Abstract][Full Text] [Related]
18.
Oka D; Yamaya N; Kuno T; Asakawa Y; Shiragiku T; Chen L; Xue J; Mamuti A; Ye F; Sun J; Ohguro K; Miyamoto H; Uematsu Y; Inagaki K; Cheng JF; Matsumoto M
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495229
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence.
Goldstein EJ; Citron DM; Tyrrell KL
Antimicrob Agents Chemother; 2014; 58(2):1187-91. PubMed ID: 24247123
[TBL] [Abstract][Full Text] [Related]
20. The
Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
